Please ensure Javascript is enabled for purposes of website accessibility

Why Syros Pharmaceuticals Stock Is Soaring Today

By Keith Speights - Dec 20, 2019 at 11:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appeared to like the addition of a well-known new board member.

What happened

Shares of Syros Pharmaceuticals (SYRS 1.46%) are soaring today, up by 15.7% as of 11:04 a.m. EST, after the company announced that Mark Alles is joining its board of directors. Alles previously served as CEO of Celgene prior to its acquisition by Bristol-Myers Squibb.

So what

The appointment of a new director wouldn't be a major catalyst for most stocks. But small biotech stocks often spike on any positive news. And the addition of Alles, a well-known industry veteran who helped build Celgene into a major player in the biotech world, is certainly a feather in Syros' cap.

Rising orange and blue stock chart on LCD screen

Image source: Getty Images.

Small biotechs often don't get a lot of publicity. But many investors are familiar with Alles' track record and will be more likely to check out the prospects for Syros with him on the company's board.

Alles' appointment comes only two days after Syros announced a collaboration with Global Blood Therapeutics. The two companies plan to work together in developing therapies targeting rare blood diseases beta-thalassemia and sickle cell disease.

Now what

There are two main things to watch for with Syros going forward. The company expects to report data from a phase 2 clinical study evaluating experimental drug SY-1425 in combination with Celgene's Vidaza in treating acute myeloid leukemia next year. Syros also hopes to initiate a phase 1 study of SY-5609 targeting solid tumors in the first quarter of 2020.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Syros Pharmaceuticals, Inc. Stock Quote
Syros Pharmaceuticals, Inc.
SYRS
$0.72 (1.46%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.